16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Implementation of “Treat‐all” at adult HIV care and treatment sites in the Global IeDEA Consortium: results from the Site Assessment Survey

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Since 2015, the World Health Organization ( WHO) has recommended that all people living with HIV ( PLHIV) initiate antiretroviral treatment ( ART), irrespective of CD4+ count or clinical stage. National adoption of universal treatment has accelerated since WHO's 2015 “Treat All” recommendation; however, little is known about the translation of this guidance into practice. This study aimed to assess the status of Treat All implementation across regions, countries, and levels of the health care delivery system.

          Methods

          Between June and December 2017, 201/221 (91%) adult HIV treatment sites that participate in the global Ie DEA research consortium completed a survey on capacity and practices related to HIV care. Located in 41 countries across seven geographic regions, sites provided information on the status and timing of site‐level introduction of Treat All, as well as site‐level practices related to ART initiation.

          Results

          Almost all sites (93%) reported that they had begun implementing Treat All, and there were no statistically significant differences in site‐level Treat All introduction by health facility type, urban/rural location, sector (public/private) or country income level. The median time between national policy adoption and site‐level introduction was one month. In countries where Treat All was not yet adopted in national guidelines, 69% of sites reported initiating all patients on ART, regardless of clinical criteria, and these sites had been implementing Treat All for a median period of seven months at the time of the survey. The majority of sites (77%) reported typically initiating patients on ART within 14 days of confirming diagnosis, with 60% to 62% of sites implementing Treat All in East, Southern and West Africa reporting same‐day ART initiation for most patients.

          Conclusions

          By mid‐ to late‐2017, the Treat All strategy was the standard of care at almost all Ie DEA sites, including rural, primary‐level health facilities in low‐resource settings. While further assessments of site‐level capacity to provide high‐quality HIV care under Treat All and to support sustained viral suppression after ART initiation are needed, the widespread introduction of Treat All at the service delivery level is a critical step towards global targets for ending the HIV epidemic as a public health threat.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England

          Background Antiretroviral treatment for HIV-infection before immunologic decline (early ART) and pre-exposure chemoprophylaxis (PrEP) can prevent HIV transmission, but routine adoption of these practices by clinicians has been limited. Methods Between September and December 2013, healthcare practitioners affiliated with a regional AIDS Education and Training Center in New England were invited to complete online surveys assessing knowledge, beliefs and practices regarding early ART and PrEP. Multivariable models were utilized to determine characteristics associated with prescribing intentions and practices. Results Surveys were completed by 184 practitioners. Respondent median age was 44 years, 58% were female, and 82% were white. Among ART-prescribing clinicians (61% of the entire sample), 64% were aware that HIV treatment guidelines from the Department of Health and Human Services recommended early ART, and 69% indicated they would prescribe ART to all HIV-infected patients irrespective of immunologic status. However, 77% of ART-prescribing clinicians would defer ART for patients not ready to initiate treatment. Three-fourths of all respondents were aware of guidance from the U.S. Centers for Disease Control and Prevention recommending PrEP provision, 19% had prescribed PrEP, and 58% of clinicians who had not prescribed PrEP anticipated future prescribing. Practitioners expressed theoretical concerns and perceived practical barriers to prescribing early ART and PrEP. Clinicians with higher percentages of HIV-infected patients (aOR 1.16 per 10% increase in proportion of patients with HIV-infection, 95% CI 1.01–1.34) and infectious diseases specialists (versus primary care physicians; aOR 3.32, 95% CI 0.98–11.2) were more likely to report intentions to prescribe early ART. Higher percentage of HIV-infected patients was also associated with having prescribed PrEP (aOR 1.19, 95% CI 1.06–1.34), whereas female gender (aOR 0.26, 95% CI 0.10–0.71) was associated with having not prescribed PrEP. Conclusions These findings suggest many clinicians have shifted towards routinely recommending early ART, but not PrEP, so interventions to facilitate PrEP provision are needed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count

            Introduction Recently published large randomized controlled trials, START, TEMPRANO and HPTN 052 show the clinical benefit of early initiation of antiretroviral treatment (ART) in HIV-infected persons and in reducing HIV transmission. The trials influenced the World Health Organization (WHO) decision to issue updated recommendations to prescribe ART to all individuals living with HIV, irrespective of age and CD4 cell count. Discussion It is clear that the new 2015 WHO recommendations if followed, will change the face of the HIV epidemic and probably curb its burden over time. Implementation however, requires that health systems, especially those in low and middle-income settings, be ready to face this challenge on a large scale. HIV prevention and treatment are easy in theory yet hard in practice. The new WHO guidelines for initiation of ART regardless of CD4 cell count will lead to upfront increases in the costs of healthcare delivery as the goal is to treat all those now newly eligible for ART. Around 22 million people living with HIV qualify and will therefore require ART. Related challenges immediately follow: firstly, that everyone must be tested for HIV; secondly, that anyone who has had an HIV test should know their result and understand its significance; and, thirdly, that every person identified as HIV-positive should receive and remain on ART. The emergence of HIV drug resistant strains when treatment is started at higher CD4 cell count thresholds is a further concern as persons on HIV treatment for longer periods of time are at increased risk of intermittent medication adherence. Conclusions The new WHO recommendations for ART are welcome, but lacking as they fail to consider meaningful solutions to the challenges inherent to implementation. They fail to incorporate actual strategies on how to disseminate and adopt these far-reaching guidelines, especially in sub-Saharan Africa, an area with weak healthcare infrastructures. Well-designed, high-quality research is needed to assess the feasibility, safety, acceptability, impact, and cost of innovations such as the universal voluntary testing and immediate treatment approaches, and broad consultation must address community, human rights, ethical, and political concerns. Electronic supplementary material The online version of this article (doi:10.1186/s40249-016-0179-9) contains supplementary material, which is available to authorized users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.

              Since the mid-1990s, effective antiretroviral therapy (ART) regimens have improved in potency, tolerability, ease of use, and class diversity. We sought to examine trends in treatment initiation and resulting human immunodeficiency virus (HIV) virologic suppression in North America between 2001 and 2009, and demographic and geographic disparities in these outcomes. We analyzed data on HIV-infected individuals newly clinically eligible for ART (ie, first reported CD4+ count<350 cells/µL or AIDS-defining illness, based on treatment guidelines during the study period) from 17 North American AIDS Cohort Collaboration on Research and Design cohorts. Outcomes included timely ART initiation (within 6 months of eligibility) and virologic suppression (≤500 copies/mL, within 1 year). We examined time trends and considered differences by geographic location, age, sex, transmission risk, race/ethnicity, CD4+ count, and viral load, and documented psychosocial barriers to ART initiation, including non-injection drug abuse, alcohol abuse, and mental illness. Among 10,692 HIV-infected individuals, the cumulative incidence of 6-month ART initiation increased from 51% in 2001 to 72% in 2009 (Ptrend<.001). The cumulative incidence of 1-year virologic suppression increased from 55% to 81%, and among ART initiators, from 84% to 93% (both Ptrend<.001). A greater number of psychosocial barriers were associated with decreased ART initiation, but not virologic suppression once ART was initiated. We found significant heterogeneity by state or province of residence (P<.001). In the last decade, timely ART initiation and virologic suppression have greatly improved in North America concurrent with the development of better-tolerated and more potent regimens, but significant barriers to treatment uptake remain, both at the individual level and systemwide.
                Bookmark

                Author and article information

                Contributors
                ellen.brazier@sph.cuny.edu
                Journal
                J Int AIDS Soc
                J Int AIDS Soc
                10.1002/(ISSN)1758-2652
                JIA2
                Journal of the International AIDS Society
                John Wiley and Sons Inc. (Hoboken )
                1758-2652
                12 July 2019
                July 2019
                : 22
                : 7 ( doiID: 10.1002/jia2.2019.22.issue-7 )
                : e25331
                Affiliations
                [ 1 ] Institute for Implementation Science in Population Health City University of New York New York NY USA
                [ 2 ] Graduate School of Public Health and Health Policy (GSPHHP) City University of New York New York NY USA
                [ 3 ] Department of Medicine Division of Infectious Diseases Vanderbilt University Medical Center Nashville TN USA
                [ 4 ] Department of Biomedical Informatics Vanderbilt University School of Medicine Nashville TN USA
                [ 5 ] Vanderbilt Institute for Global Health (VIGH) Nashville TN USA
                [ 6 ] National AIDS Control Programme Dar es Salaam Tanzania
                [ 7 ] TREAT Asia, amfAR The Foundation for AIDS Research Bangkok Thailand
                [ 8 ] Bloomberg School of Public Health Johns Hopkins University Baltimore MD USA
                [ 9 ] School of Public Health and Family Medicine Faculty of Health Sciences University of Cape Town Cape Town South Africa
                [ 10 ] Hôpital de Jour, Service des Maladies Infectieuses, CHU Souro Sanou Bobo‐Dioulasso Burkina Faso
                [ 11 ] Institut Supérieur des Sciences de la Santé (INSSA) Université Nazi Boni Bobo‐Dioulasso Burkina Faso
                [ 12 ] School of Medicine Indiana University Indianapolis IN USA
                [ 13 ] Clinical and Research Center of Infectious Diseases Beijing Ditan Hospital Capital Medical University Beijing China
                [ 14 ] Institute of Social and Preventive Medicine University of Bern Bern Switzerland
                [ 15 ] School of Medicine Virginia Commonwealth University Richmond VA USA
                [ 16 ] College of Public Health The Ohio State University Columbus OH USA
                Author notes
                [*] [* ] Corresponding author: Ellen Brazier, 55, West 125th Street, 6th Floor, New York City, New York 10027, USA. Tel: +1 646‐364‐9622. ( ellen.brazier@ 123456sph.cuny.edu )
                Author information
                https://orcid.org/0000-0002-8514-1958
                https://orcid.org/0000-0002-8417-0650
                https://orcid.org/0000-0002-8375-3926
                https://orcid.org/0000-0002-3966-8476
                https://orcid.org/0000-0003-2110-2631
                https://orcid.org/0000-0002-3280-5386
                Article
                JIA225331
                10.1002/jia2.25331
                6625339
                31623428
                0fbf0429-6cb2-4691-827c-0a89f1a195ee
                © 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 30 October 2018
                : 29 May 2019
                Page count
                Figures: 2, Tables: 3, Pages: 12, Words: 2009
                Funding
                Funded by: National Institute of Allergy and Infectious Diseases
                Award ID: U01AI069907
                Award ID: U01AI069911
                Award ID: U01AI069918
                Award ID: U01AI069919
                Award ID: U01AI069923
                Award ID: U01AI069924
                Award ID: U01AI096299
                Funded by: Eunice Kennedy Shriver National Institute of Child Health and Human Development
                Funded by: National Cancer Institute
                Funded by: National Institute of Mental Health
                Funded by: National Institute on Drug Abuse
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                jia225331
                July 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.5 mode:remove_FC converted:12.07.2019

                Infectious disease & Microbiology
                hiv,“treat all”,antiretroviral treatment,hiv care,guideline implementation

                Comments

                Comment on this article